Literature DB >> 25817267

Red blood cells alloimmunization and autoimmunization among transfusion-dependent beta-thalassemia patients in Alexandria province, Egypt.

Jamil M A S Obaid1, Salma Y Abo El-Nazar2, Amal M Ghanem3, Abeer S El-Hadidi4, Basma H M Mersal2.   

Abstract

BACKGROUND: Beta thalassemia is considered a severe, progressive anemia, which needs regular transfusions for life expectancy. One of the most important complications of regular blood transfusions is autoimmunization and alloimmunization, which increases the need for transfusion. This study was performed to investigate the frequency of auto- and allo-antibodies in beta thalassemia patients in Alexandria, Egypt.
MATERIALS AND METHODS: Blood samples of fourteen beta thalassemia patients were collected and tested for autosensitization with direct antiglobulin test (DAT). The positive DAT blood sample undergone antibody elution then identification. Plasma of the patients were also investigated for allosensitization by testing against cell panel reagents.
RESULTS: DAT was positive in 45% of the patients. Eluted antibodies were identified in 6 cases of 10, they were Kp(b) and Lu(b), and one positive test was unidentified. Alloantibodies were detected in 42.5% of the cases. The identified antibodies were anti-D (4.76%), anti-c (4.76%), anti-K (4.76%), anti-Kp(a) (9.52%), anti-Kp(b) (19.05%), anti-Lu(a) (9.52%), anti-Lu(b) (19.05%), and anti-Bg(a) (4.76%). A total 23.81% of the alloantibodies were unidentified. DISCUSSION: This study observes that autoimmunization and alloimmunization were more frequent among poly transfused beta thalassemia Egyptian patients. The presence of these clinically significant alloantibodies is a bad indicator for situation of blood transfusion. There is need for use an effective strategies to provide a safe blood for those patients by using leukodepleted blood and more compatible blood with extended phenotyping.
Copyright © 2015. Published by Elsevier Ltd.

Entities:  

Keywords:  Erythrocytes; Hemolysis; Sensitization; Thalassemia; Transfusion

Mesh:

Substances:

Year:  2015        PMID: 25817267     DOI: 10.1016/j.transci.2015.03.006

Source DB:  PubMed          Journal:  Transfus Apher Sci        ISSN: 1473-0502            Impact factor:   1.764


  5 in total

1.  Red blood cell alloimmunisation in transfusion-dependent thalassaemia: a systematic review.

Authors:  Massimo Franchini; Gian Luca Forni; Giuseppe Marano; Mario Cruciani; Carlo Mengoli; Valeria Pinto; Lucia De Franceschi; Donatella Venturelli; Maddalena Casale; Martina Amerini; Martina Capuzzo; Giuliano Grazzini; Francesca Masiello; Ilaria Pati; Eva Veropalumbo; Stefania Vaglio; Simonetta Pupella; Giancarlo M Liumbruno
Journal:  Blood Transfus       Date:  2019-01       Impact factor: 3.443

2.  Red Blood Cell Immunization and Contributing Factors in 685 Thalassemia Patients.

Authors:  Mojgan Shaiegan; Mostafa Moghaddam; Mahtab Maghsudlu; Azita Azarkeivan; Sima Zolfaghari; Ali-Akbar Pourfatollah; Peyman Soleimanzadeh; Ehsan Shahverdi
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2022-01-01

3.  A study of red blood cell alloimmunization and autoimmunization among 200 multitransfused Egyptian β thalassemia patients.

Authors:  Amal El-Beshlawy; Alshymaa Ahmed Salama; Mohamed Roshdy El-Masry; Noha M El Husseiny; Asmaa M Abdelhameed
Journal:  Sci Rep       Date:  2020-12-03       Impact factor: 4.379

4.  Clinical and epidemiological profile of alloimmunized and autoimmunized multi-transfused patients against red blood cell antigens in a blood center of Minas Gerais.

Authors:  Orsetti Gomes do Valle Neto; Vitor Mendonça Alves; Gilberto de Araújo Pereira; Helio Moraes-Souza; Paulo Roberto Juliano Martins
Journal:  Hematol Transfus Cell Ther       Date:  2018-02-17

5.  Study of Frequency and Characteristics of Red Blood Cell Alloimmunization in Thalassemic Patients: Multicenter Study from Palestine.

Authors:  Adham Abu Taha; Ahmad Yaseen; Sa'd Suleiman; Omar Abu Zenah; Hammam Ali; Rania Abu Seir; Khaled Younis
Journal:  Adv Hematol       Date:  2019-11-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.